Page last updated: 2024-08-16

proguanil and Behavior Disorders

proguanil has been researched along with Behavior Disorders in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Odenholt, I; Petersson, H; Rietz, G1
Barrett, PJ; Bradley, DJ; Clarke, PD; Emmins, PD1
Behrens, RH; Corbett, EL; Doherty, JP1
Dollow, S1

Other Studies

5 other study(ies) available for proguanil and Behavior Disorders

ArticleYear
[Many travellers suffer of side-effects of malaria prophylaxis].
    Lakartidningen, 2002, Jun-27, Volume: 99, Issue:26-27

    Topics: Antimalarials; Chloroquine; Drug Eruptions; Gastrointestinal Diseases; Humans; Malaria; Mefloquine; Mental Disorders; Proguanil; Surveys and Questionnaires; Travel

2002
Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers.
    BMJ (Clinical research ed.), 1996, Aug-31, Volume: 313, Issue:7056

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Health Surveys; Hospitalization; Humans; Malaria; Male; Mefloquine; Mental Disorders; Nervous System Diseases; Proguanil; Retrospective Studies; Travel; Treatment Refusal; United Kingdom

1996
Adverse events associated with mefloquine. Study in returned travellers confirms authors' findings.
    BMJ (Clinical research ed.), 1996, Dec-14, Volume: 313, Issue:7071

    Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Humans; Mefloquine; Mental Disorders; Proguanil; Travel

1996
Adverse events associated with mefloquine. Risk-benefit ratio must be taken into account.
    BMJ (Clinical research ed.), 1996, Dec-14, Volume: 313, Issue:7071

    Topics: Antimalarials; Chloroquine; Drug Combinations; Humans; Mefloquine; Mental Disorders; Proguanil; Risk Factors; Travel

1996
Lariam's legacy.
    Consumer reports, 2002, Volume: 67, Issue:3

    Topics: Antimalarials; Consumer Product Safety; Doxycycline; Drug Costs; Humans; Malaria; Mefloquine; Mental Disorders; Naphthoquinones; Proguanil; United States; United States Food and Drug Administration

2002